Oculis to Present at Upcoming March Investor Conference
Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC), a global biopharmaceutical company focused on eye care and sight preservation, has announced its participation in the upcoming Leerink Global Healthcare Conference.
The company's Chief Financial Officer, Sylvia Cheung, will present on March 11, 2025, at 3:00pm ET in Miami Beach, FL. Investors can request one-on-one meetings through their institutional representatives.
A live webcast of the fireside chat will be accessible through the Events and Presentations section of the Oculis website under Investors & Media.
Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC), un'azienda biofarmaceutica globale focalizzata sulla cura degli occhi e sulla preservazione della vista, ha annunciato la sua partecipazione alla prossima Leerink Global Healthcare Conference.
Il Chief Financial Officer dell'azienda, Sylvia Cheung, presenterà il 11 marzo 2025, alle 15:00 ET a Miami Beach, FL. Gli investitori possono richiedere incontri individuali tramite i loro rappresentanti istituzionali.
Una trasmissione in diretta della conversazione sarà accessibile attraverso la sezione Eventi e Presentazioni del sito web di Oculis, sotto Investitori e Media.
Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC), una empresa biofarmacéutica global centrada en el cuidado ocular y la preservación de la vista, ha anunciado su participación en la próxima Leerink Global Healthcare Conference.
La Directora Financiera de la empresa, Sylvia Cheung, presentará el 11 de marzo de 2025, a las 3:00pm ET en Miami Beach, FL. Los inversores pueden solicitar reuniones uno a uno a través de sus representantes institucionales.
Una transmisión en vivo de la charla estará disponible en la sección de Eventos y Presentaciones del sitio web de Oculis bajo Inversores y Medios.
Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC)은 안구 관리 및 시력 보존에 중점을 둔 글로벌 생명공학 회사로, 다가오는 Leerink Global Healthcare Conference에 참여한다고 발표했습니다.
회사의 최고 재무 책임자인 Sylvia Cheung은 2025년 3월 11일 오후 3시 ET에 플로리다주 마이애미 비치에서 발표할 예정입니다. 투자자는 기관 대표를 통해 일대일 미팅을 요청할 수 있습니다.
대화의 생중계는 Oculis 웹사이트의 투자자 및 미디어 섹션의 이벤트 및 발표 섹션에서 접근할 수 있습니다.
Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC), une entreprise biopharmaceutique mondiale axée sur les soins oculaires et la préservation de la vue, a annoncé sa participation à la prochaine Leerink Global Healthcare Conference.
La Directrice Financière de l'entreprise, Sylvia Cheung, présentera le 11 mars 2025 à 15h00 ET à Miami Beach, FL. Les investisseurs peuvent demander des réunions individuelles par l'intermédiaire de leurs représentants institutionnels.
Un webinaire en direct de la discussion sera accessible via la section Événements et Présentations du site web d'Oculis, sous Investisseurs et Médias.
Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC), ein globales biopharmazeutisches Unternehmen, das sich auf Augenpflege und den Erhalt des Sehens konzentriert, hat seine Teilnahme an der bevorstehenden Leerink Global Healthcare Conference angekündigt.
Die Chief Financial Officer des Unternehmens, Sylvia Cheung, wird am 11. März 2025 um 15:00 Uhr ET in Miami Beach, FL, präsentieren. Investoren können über ihre institutionellen Vertreter Einzelgespräche anfragen.
Ein Live-Stream des Gesprächs wird über den Bereich Veranstaltungen und Präsentationen auf der Oculis-Website unter Investoren & Medien verfügbar sein.
- None.
- None.
ZUG, Switzerland, March 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Oculis will be attending and presenting at the following upcoming investor conference:
Leerink Global Healthcare Conference
Presenter: Sylvia Cheung, Chief Financial Officer
Presentation date and time: March 11, 2025 at 3:00pm ET
Location: Miami Beach, FL
The Company will be available for one-on-one meetings during the conference. Interested investors should contact their respective representative at the sponsoring institution to request meetings.
A live webcast of the fireside chat can also be accessed by visiting the Oculis website on the Events and Presentations section under Investors & Media.
About Oculis
Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) purposefully driven to save sight and improve eye care. Oculis’ highly differentiated pipeline of multiple innovative product candidates in development includes: OCS-01, a topical eye drop candidate for diabetic macular edema; Privosegtor (OCS-05), a neuroprotective candidate for acute optic neuritis with potentially broad clinical applications in other neuro-ophthalmic diseases and Licaminlimab (OCS-02), a topical biologic anti-TNFα eye drop candidate for dry eye disease. Headquartered in Switzerland with operations in the U.S. and Iceland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors.
For more information, please visit: www.oculis.com
Oculis Contacts
Ms. Sylvia Cheung, CFO
sylvia.cheung@oculis.com
Investor & Media Relations
LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com
FAQ
When is Oculis (OCS) presenting at the Leerink Global Healthcare Conference 2025?
Who will represent Oculis (OCS) at the Leerink Global Healthcare Conference?
How can investors access Oculis (OCS) presentation at the Leerink Conference?
How can investors schedule meetings with Oculis (OCS) management at the Leerink Conference?
